Viridiana Arreola

Viridiana Arreola

Auto-generated profile, based on publicly available information

Viridiana Arreola

Gastrointestinal Physiology Laboratory, Hospital de Mataró, Universitat Autónoma de Barcelona, Mataró, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2019 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
MBMireia Bolívar-Prados
Mireia Bolívar-Prados
LRLaia Rofes
Laia Rofes
VAViridiana Arreola
Viridiana Arreola
SGSonia Guida
Sonia Guida
WNWeslania Viviane Nascimento
Weslania Viviane Nascimento
Pere ClavéPere Clavé
Pere Clavé
Background: Increasing viscosity with thickening agents is a valid therapeutic strategy for oropharyngeal dysphagia (OD). To assess the therapeutic effect of a xanthan gum‐based thickener (Nutilis Clear®) at six viscosities compared with thin liquid in poststroke OD (PSOD) patients.Methods: A total of 120 patients with PSOD were studied in this controlled, multiple‐dose, fixed‐order, and single‐blind study using videofluoroscopy (VFSS). A series of boluses of 10 mL thin liquid and 2000, 1400, 800, 450, 250, and 150 mPa s viscosities were given in duplicate, interrupted in case of aspiration. We assessed the safety and efficacy of swallow and the kinematics of the swallow response.Key Results: A total of 41.2% patients had safe swallow at thin liquid which significantly increased for all viscosities from 71.9% at 150 mPa s to 95.6% at 1400 mPa s (P < .001). PAS score (3.7 ± 2.3) at thin liquid was also reduced by increasing bolus viscosity (P < .001). The prevalence of patients with aspiration at thin liquid was 17.5% and decreased at all viscosities (P < .01), except at 150 mPa s. Increasing viscosity shortened time to laryngeal vestibule closure (LVC) at all viscosities (P < .01) and reduced bolus velocity at ≥450 mPa s (P < .05). The prevalence of patients with pharyngeal residue at each viscosity 37.7%‐44.7% was similar to that at thin liquid (41.2%).Conclusions and Inferences: The prevalence of unsafe swallow with thin liquids is very high in PSOD. Increasing shear bolus viscosity with this xanthan gum‐based thickener significantly increased the safety of swallow in patients with PSOD in a viscosity‐dependent manner without increasing the prevalence of pharyngeal residue.

1 December 2022 in Clinical Nutrition
Verified
Journal Article
Open access
AMAlberto Martin–Martinez
Alberto Martin–Martinez
OOOmar Ortega
Omar Ortega
PVPaula Viñas
Paula Viñas
VAViridiana Arreola
Viridiana Arreola
WNWeslania Viviane Nascimento
Weslania Viviane Nascimento
Pere ClavéPere Clavé
Pere Clavé
Prevalence and complications of oropharyngeal dysphagia (OD) and malnutrition (MN) in COVID-19 patients is unknown. Our aim was to assess the prevalence, risk factors and clinical outcomes of OD and MN in a general hospital during the first wave of the COVID-19 pandemic. This was a prospective, observational study involving clinical assessment of OD (Volume-Viscosity Swallowing Test), and nutritional screening (NRS2002) and assessment (GLIM criteria) in COVID-19 patients hospitalized in general wards at the Consorci Sanitari del Maresme, Catalonia, Spain. The clinical characteristics and outcomes of patients were assessed at pre-admission, admission and discharge, and after 3 and 6-months follow-up. We included 205 consecutive patients (69.28 ± 17.52 years, Charlson 3.74 ± 2.62, mean hospital stay 16.8 ± 13.0 days). At admission, Barthel Index was 81.3 ± 30.3; BMI 28.5 ± 5.4 kg/m2; OD prevalence 51.7% (44.1% impaired safety of swallow); and 45.5% developed MN with a mean weight loss of 10.1 ± 5.0 kg during hospitalization. OD was an independent risk factor for MN during hospitalization (OR 3.96 [1.45–10.75]), and hospitalization was prolonged in patients with MN compared with those without (21.9 ± 14.8 vs 11.9 ± 8.9 days, respectively; p < 0.0001). OD was independently associated with comorbidities, neurological symptoms, and low functionality. At 6-month follow-up, prevalence of OD was still 23.3% and that of MN only 7.1%. Patients with OD at discharge showed reduced 6-month survival than those without OD at discharge (71.6% vs 92.9%, p < 0.001); in contrast, those with MN at discharge did not show 6-month survival differences compared to those without (85.4% vs 83.8%, p = 0.8). Prevalence and burden of OD and MN in patients hospitalized in COVID-19 wards is very high. Our results suggest that optimizing the management of MN might shorten the hospitalization period but optimizing the management of OD will likely impact the nutritional status of COVID-19 patients and improve their clinical outcomes and survival after hospital discharge. ClinicalTrials.gov Identifier: NCT04346212.

16 February 2020 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
NTNoemí Tomsen
Noemí Tomsen
DADaniel Alvarez‐Berdugo
Daniel Alvarez‐Berdugo
LRLaia Rofes
Laia Rofes
OOOmar Ortega
Omar Ortega
VAViridiana Arreola
Viridiana Arreola
SMStephanie Michlig
Stephanie Michlig
Background: Oropharyngeal dysphagia (OD) treatment is moving away from compensatory strategies toward active treatments that improve swallowing function. The aim of this study was to assess the acute therapeutic effect of TRPA1/M8 agonists in improving swallowing function in OD patients.Methods: Fifty‐eight patients with OD caused by aging, stroke, or neurodegenerative disease were included in a three‐arm, quadruple‐blind, randomized clinical trial (NCT02193438). Swallowing safety and efficacy and the kinematics of the swallow response were assessed by videofluoroscopy (VFS) during the swallow of 182 ± 2 mPa·s viscosity (nectar) boluses of a xanthan gum thickener supplemented with (a) 756.6 μmol/L cinnamaldehyde and 70 μmol/L zinc (CIN‐Zn) (TRPA1 agonists), (b) 1.6 mmol/L citral (CIT) (TRPA1 agonist), or (c) 1.6 mmol/L citral and 1.3 mmol/L isopulegol (CIT‐ISO) (TRPA1 and TRPM8 agonists). The effects on pharyngeal event‐related potentials (ERP) were assessed by electroencephalography.Key Results: TRPA1 stimulation with either CIN‐Zn or CIT reduced time to laryngeal vestibule closure (CIN‐Zn P = .002, CIT P = .023) and upper esophageal sphincter opening (CIN‐Zn P = .007, CIT P = .035). In addition, CIN‐Zn reduced the penetration‐aspiration scale score (P = .009), increased the prevalence of safe swallows (P = .041), and reduced the latency of the P2 peak of the ERP. CIT‐ISO had no positive effect on biomechanics or neurophysiology. No significant adverse events were observed.Conclusions and Inferences: TRPA1 stimulation with CIN‐Zn or CIT improves the swallow response which, in the case of CIN‐Zn, is associated with a significant improvement in cortical activation and safety of swallow. These results provide the basis for the development of new active treatments for OD using TRPA1 agonists.